Publication: Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development
Issued Date
2007-10-01
Resource Type
ISSN
00029637
Other identifier(s)
2-s2.0-38449090020
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
American Journal of Tropical Medicine and Hygiene. Vol.77, No.4 (2007), 779-789
Suggested Citation
Ernest Beutler, Stephan Duparc, Ogobara Doumbo, Kanjaksha Ghosh, Marcus Vinicius Guimaraes De Lacerda, Didier Lapierre, Sornchai Looareesuwan, Zulfiqarali Premji, Tom Vulliamy, Christopher Whitty Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. American Journal of Tropical Medicine and Hygiene. Vol.77, No.4 (2007), 779-789. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/24511
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development
Other Contributor(s)
Scripps Research Institute
International Center Cointrin
University of Bamako Faculty of Medicine, Pharmacy and Odonto-Stomatology
Institute of Immunohaematology Mumbai
Fundacao de Medicina Tropical do Amazonas
GlaxoSmithKline plc.
Mahidol University
University of Dar Es Salaam
Imperial College London
London School of Hygiene & Tropical Medicine
International Center Cointrin
University of Bamako Faculty of Medicine, Pharmacy and Odonto-Stomatology
Institute of Immunohaematology Mumbai
Fundacao de Medicina Tropical do Amazonas
GlaxoSmithKline plc.
Mahidol University
University of Dar Es Salaam
Imperial College London
London School of Hygiene & Tropical Medicine
Abstract
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is relatively common in populations exposed to malaria. This deficiency appears to provide some protection from this infection, but it can also cause hemolysis after administration of some antimalarial drugs, especially primaquine. The risk of drug-induced G6PD deficiency-related hemolysis depends on a number of factors including the G6PD variant, the drug and drug dosage schedule, patient status, and disease factors. Although a great deal is known about the molecular biology of G6PD, determining the potential for drug-induced hemolysis in the clinical setting is still challenging. This report discusses the potential strategies for assessing drug-induced G6PD deficiency-related hemolytic risk preclinically and in early clinical trials. Additionally, the issues important for conducting larger clinical trials in populations in which G6PD deficiency is prevalent are examined, with a particular focus on antimalarial drug development. Copyright © 2007 by The American Society of Tropical Medicine and Hygiene.